Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
NCT05302778
·
clinicaltrials.gov ↗
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer
Sponsor
University of Milano Bicocca
Collaborators
[object Object]